Navigation Links
Kiadis Pharma to Receive GMP Manufacturing License and GMP Certificate

AMSTERDAM, July 23, 2013 /PRNewswire/ --

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that its Quality Control (QC) laboratory and the associated Quality system has been inspected for good-manufacturing-practice (GMP) by the Dutch Health Care Inspectorate (IGZ) and has fully met the EU GMP standards. As a result, Kiadis Pharma will receive a GMP manufacturing license and GMP certificate for its QC laboratory from the Dutch Ministry of Health, Welfare and Sport.  

GMP licensing and certification enables Kiadis Pharma to perform QC release-assays for the clinical trial manufacturing of the Company's lead product ATIR™, a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients.

Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: "This is an important milestone for Kiadis Pharma as we are committed to the highest standards of manufacturing. We are delighted that our QC laboratory and the associated Quality system will receive a GMP manufacturing license and GMP certificate. This not only attests to the quality that we have established at Kiadis Pharma, but secures the pathway to take ATIR™ to the next stage of development. ATIR™ is currently in an ongoing Phase II study to confirm and extend some exciting data. We expect the Phase II results in H1 2014."

About ATIR™

ATIR™ is a cell based medicinal product enabling stem cell transplantations using partially mismatched (haploidentical) family members as donors for patients suffering from blood cancer who lack a suitable standard of care matched donor. Stem cell transplantation is the only potentially curative treatment for many patients but a matching donor is available for only half of the patients in need. ATIR™ thus has the potential to address this unmet need and to make stem cell transplantations available for all patients worldwide.

Those T-cells in a haploidentical graft which would cause Graft-versus-Host-Disease (GvHD) are selectively eliminated using proprietary technology to produce ATIR™. ATIR™ is administered as an adjunctive treatment after a haploidentical stem cell transplantation facilitating early immune reconstitution without causing life-threatening (acute) GvHD.

In a Phase I/II study with ATIR™, safety and proof of concept were confirmed in terms of absence of grade III/IV GvHD, reduced rates of infection, reduced Transplant Related Mortality and high Overall Survival.

ATIR™ is currently in Phase II clinical development and has been granted Orphan Drug Designation both in the EU and the USA. In these regions, 20,000 to 25,000 patients a year are unable to find a suitable standard of care matched donor. Together, both regions represent a combined primary market potential of more than EUR 1 billion per year.

About Kiadis Pharma

Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company developing innovative and potentially life-saving therapies for patients with late stage blood cancers and related disorders who are in need of a transplant, an area of significant unmet medical need.

Kiadis Pharma's lead product is ATIR™, a cell based product currently in Phase II development, which is designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors. Kiadis Pharma is collaborating with internationally renowned centers in Europe and North America for the successful development and manufacturing of ATIR™.

Kiadis Pharma is supported by a strong group of leading international investors including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM. Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at:

Company Contact:
Manfred Ruediger, CEO
Kiadis Pharma
Entrada 231-234
The Netherlands
Tel. +31-20-314-02-50

Media and Investor Contact:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
Tel: +44-(0)207-920-2333

SOURCE Kiadis Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. State Exchanges And Other Post-ACA Implementation Hinder 2014 Planning For Pharma
3. CRO Solutions, Inc. Announces Opening of New Division - VxP Pharma Services, Inc.
4. Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
5. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
6. ANI Pharmaceuticals, Inc. Announces Date for Second Quarter 2013 Earnings Release
7. QRxPharma Announces Collaboration With Aesica
8. Aquavit Pharmaceuticals and U-Bio Med Enter Exclusive Worldwide License Agreement for Microneedle Technology (AQT-001)
9. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
10. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
11. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
Post Your Comments:
(Date:10/9/2015)... Oct. 9, 2015  Eli Lilly and Company (NYSE: ... has acquired worldwide rights to Locemia,s intranasal glucagon, a ... treated with insulin. Intranasal glucagon, which is currently in ... needle-free rescue treatment for severe hypoglycemia. ... a proprietary glucagon nasal powder formulation that is delivered ...
(Date:10/9/2015)... HILL, N.C. , Oct. 9, 2015 /PRNewswire/ ... or Medical Device environments, corporate communications is perpetually ... communications, corporations and professionals must continuously adjust their ... effectiveness of these adjustments is difficult, but also ... today,s communication options. --> ...
(Date:10/9/2015)... -- Regulatory affairs groups within medical device organizations face a ... These specialized groups are charged with ensuring that their ... to the development and marketing of medical device products. While ... their own internal effectiveness and efficiencies to remain productive and ... --> Optimal resourcing and staffing help ...
Breaking Medicine Technology:
... 2011 SinoFresh® HealthCare, Inc., (Pink Sheets: ... with three high volume sales agencies. These sales brokerage ... long term sales and distribution along the Eastern Corridor ... Homeopathic Nasal and Sinus Care Spray available to a ...
... 29, 2011 McNeil Consumer Healthcare, Division of McNEIL-PPC, ... Hour Extended Release Caplets 150 count bottles distributed in ... part of our ongoing surveillance and monitoring efforts that ... or moldy odor. The uncharacteristic odor is thought to ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
(Date:10/9/2015)... WASHINGTON, NH (PRWEB) , ... October 09, 2015 , ... ... Sore Throat Home Exam Aid, is now available online ( ) – just ... and Prevention (CDC) says officially begins in October. However, for many in the U.S., ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... a special promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. ... are almost invisible against the teeth, which allow patients to complete treatment in ...
(Date:10/9/2015)... ... 09, 2015 , ... The Asthma and Allergy Foundation of America (AAFA) has ... Prevention (CDC) to improve the knowledge and skills of underserved adults with asthma. This ... by the CDC and allows AAFA to continue vital efforts to educate people living ...
(Date:10/9/2015)... Columbus, Ohio (PRWEB) , ... October 09, 2015 ... ... the United States, is welcoming individuals from all walks of life to save ... For the set price of $25 per month per medication, individuals and families ...
Breaking Medicine News(10 mins):
... BEIJING, June 9 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC ... partner in China, Beijing RainEarth Technology Co. Ltd., ("China,RainEarth"), ... of,blood dialysis. , This second ... include: a lower broken membrane rate, a higher gap ...
... issued a position paper on the safety of HCA as ... of extracts and GarCitrin(R). This paper, which reviews and analyzes ... component hydroxycitric acid and its salts, is available to download ... . , , ...
... , WOODCLIFF LAKE, N.J., June 9 Par Pharmaceutical Companies, ... began shipping calcitonin-salmon nasal spray to the trade. Calcitonin-salmon ... . Annual U.S. sales of Miacalcin were approximately $112 ... , , Important information about calcitonin-salmon nasal spray ...
... , Center will be the first in the world to ... to deliver blood and complementary imaging tests for solid tumor ... Canary Foundation, a nonprofit organization that funds research in early ... announced their commitment of $20 million to create the Canary ...
... Electronic Pharmacy Record (EPR) to Integrate with Microsoft(R) HealthVault(TM) ... PDX and have entered into a strategic agreement ... for multiple chain and independent pharmacy clients, available to ... aggregated prescription data. The agreement enables any pharmacy using ...
... Corporation, a leader in improving caregiver workflow in healthcare environments, ... J. Rizzo to its board of directors. , , ... our board to help broaden the business and operating base ... CEO of ThinIdentity. "Both Bill and Carol will bring strong ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: